Meeting
2017 ASCO Annual Meeting
Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1/2 clinical trial.
Authors
Jorge A. Garcia
Cleveland Clinic Taussig Cancer Insitute, Cleveland, OH
Jorge A. Garcia , Robert Dreicer , Allan J. Pantuck , Naomi B. Haas , Ulka N. Vaishampayan , Niranjan Sathyanarayana Rao , Louis J. Denis , Anthony W. Tolcher
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02349139
Citation
J Clin Oncol 35, 2017 (suppl; abstr 5041)
DOI
10.1200/JCO.2017.35.15_suppl.5041
Abstract #
5041
Poster Bd #
115
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Jorge A. Garcia
Poster
2015 ASCO Annual Meeting
Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Edwin M. Posadas
Poster
2022 ASCO Annual Meeting
A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Ulka N. Vaishampayan
Poster
2017 ASCO Annual Meeting
Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Evan Y. Yu